BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445. [PMID: 10757381 DOI: 10.1016/s1072-7515(00)00222-2] [Cited by in Crossref: 437] [Cited by in F6Publishing: 138] [Article Influence: 19.9] [Reference Citation Analysis]
Number Citing Articles
1 Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2010;14:541-548. [PMID: 19997980 DOI: 10.1007/s11605-009-1115-0] [Cited by in Crossref: 171] [Cited by in F6Publishing: 150] [Article Influence: 13.2] [Reference Citation Analysis]
2 Maxwell JE, Sherman SK, Howe JR. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2016;22:5022-9. [PMID: 27742788 DOI: 10.1158/1078-0432.CCR-16-0435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
3 Gaba RC, Mendoza-Elias N, Morrison JD, Valeshabad AK, Lipnik AJ. Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors. Semin Intervent Radiol 2017;34:101-8. [PMID: 28579677 DOI: 10.1055/s-0037-1602590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz M. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8:208-212. [PMID: 15036197 DOI: 10.1016/j.gassur.2003.11.010] [Cited by in Crossref: 99] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
5 Callahan AF, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, Melstrom L. Surgical Intervention in Gastric Carcinoid is Associated With Improved Survival in Local and Regional Disease. Am J Clin Oncol 2018;41:882-7. [PMID: 28763328 DOI: 10.1097/COC.0000000000000392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, Hackert T, Diener MK, Büchler MW, Ulrich A. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg. 2015;400:715-723. [PMID: 26198970 DOI: 10.1007/s00423-015-1323-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
7 Wei IH, Harmon CM, Arcerito M, Cheng DF, Minter RM, Simeone DM. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Ann Surg 2014;260:1088-94. [PMID: 25389924 DOI: 10.1097/SLA.0000000000000262] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
8 Poggi G, Villani L, Bernardo G. Multimodality treatment of unresectable hepatic metastases from pancreatic glucagonoma. Rare Tumors 2009;1:e6. [PMID: 21139900 DOI: 10.4081/rt.2009.e6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 House MG, Cameron JL, Lillemoe KD, Schulick RD, Choti MA, Hansel DE, Hruban RH, Maitra A, Yeo CJ. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138-145. [PMID: 16368504 DOI: 10.1016/j.gassur.2005.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
10 Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159:320-333. [PMID: 26454679 DOI: 10.1016/j.surg.2015.05.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
11 Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC, Marques HP, Weiss M, Maithel SK, Pawlik TM. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg 2017;21:2039-47. [PMID: 28744737 DOI: 10.1007/s11605-017-3491-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
12 Jilesen AP, Klümpen HJ, Busch OR, van Gulik TM, van Lienden KP, Gouma DJ, Nieveen van Dijkum EJ. Selective Arterial Embolization of Liver Metastases from Gastrinomas: A Single-Centre Experience. ISRN Hepatol 2013;2013:174608. [PMID: 27335824 DOI: 10.1155/2013/174608] [Reference Citation Analysis]
13 Gomez D, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 2007;9:345-51. [PMID: 18345317 DOI: 10.1080/13651820701504199] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
14 Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783; discussion 783-785. [PMID: 15849513 DOI: 10.1097/01.sla.0000161981.58631.ab] [Cited by in Crossref: 250] [Cited by in F6Publishing: 213] [Article Influence: 14.7] [Reference Citation Analysis]
15 Buicko JL, Finnerty BM, Zhang T, Kim BJ, Fahey TJ, Nancy Du YC. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Ann Pancreat Cancer. 2019;2. [PMID: 31535089 DOI: 10.21037/apc.2019.06.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
17 Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6:180-194. [PMID: 25057304 DOI: 10.1177/1758834014529175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
18 Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gönen M, Espat NJ, Klimstra DS, D'Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, Tang LH. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. HPB (Oxford) 2010;12:674-83. [PMID: 21083792 DOI: 10.1111/j.1477-2574.2010.00231.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
19 Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clin Pathol 2018;18:3. [PMID: 29507528 DOI: 10.1186/s12907-018-0070-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
20 Cohen MP, Herman P, Chojniak R, Poli MR, Barbosa PN, Bitencourt AG. Focused abdominal ultrasound in preoperative liver surgery staging: a prospective study. World J Surg Oncol 2013;11:138. [PMID: 23768101 DOI: 10.1186/1477-7819-11-138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Shao QQ, Zhao BB, Dong LB, Cao HT, Wang WB. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol 2019; 25(32): 4673-4681 [PMID: 31528093 DOI: 10.3748/wjg.v25.i32.4673] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Williamson JM, Anderson J, Spalding DR. Surgical resection of hepatic and cardiac neuroendocrine metastases from a caecal primary tumour. Ann R Coll Surg Engl 2014;96:e7-8. [PMID: 24780655 DOI: 10.1308/003588414X13814021676954] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
23 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
24 Thiels CA, Bergquist JR, Laan DV, Croome KP, Smoot RL, Nagorney DM, Thompson GB, Kendrick ML, Farnell MB, Truty MJ. Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified? J Gastrointest Surg. 2016;20:891-898. [PMID: 26925796 DOI: 10.1007/s11605-016-3102-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Liu Q, Wang J, Sun C, Xu J. The diagnosis and management of rare cystic liver metastases from nasopharyngeal carcinoma: A case report. Medicine (Baltimore) 2018;97:e11257. [PMID: 29952994 DOI: 10.1097/MD.0000000000011257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534-545. [PMID: 25962092 DOI: 10.4158/ep14464.dsc] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Shaheen M, Hassanain M, Aljiffry M, Cabrera T, Chaudhury P, Simoneau E, Kongkaewpaisarn N, Salman A, Rivera J, Jamal M. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012;14:60-66. [PMID: 22151453 DOI: 10.1111/j.1477-2574.2011.00405.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
28 Pan M, Yang Y, Teng T, Lu F, Chen Y, Huang H. Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study. BMC Gastroenterol 2021;21:101. [PMID: 33663420 DOI: 10.1186/s12876-021-01685-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525 [PMID: 26327759 DOI: 10.3748/wjg.v21.i32.9512] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
30 Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(36): 4519-4525 [PMID: 20857521 DOI: 10.3748/wjg.v16.i36.4519] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
31 Lee SY, Cheow PC, Teo JY, Ooi LL. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol 2012;2012:146590. [PMID: 22319650 DOI: 10.1155/2012/146590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
32 Kose E, Kahramangil B, Aydin H, Donmez M, Takahashi H, Aucejo F, Siperstein A, Berber E. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc. 2020;34:249-256. [PMID: 30945061 DOI: 10.1007/s00464-019-06759-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
33 Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg. 2011;396:299-311. [PMID: 21279821 DOI: 10.1007/s00423-011-0741-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
34 Kwon YK, Etesami K, Genyk Y. Should living donor liver transplant selection be subject to the same restrictions as deceased donor transplant? Curr Opin Organ Transplant 2020;25:47-51. [PMID: 31834006 DOI: 10.1097/MOT.0000000000000728] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg 2018;7:28-35. [PMID: 29629317 DOI: 10.21037/gs.2017.11.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
36 White RR. Pancreatic neuroendocrine tumors: selection, selection, selection…. J Surg Res 2011;167:211-3. [PMID: 20855087 DOI: 10.1016/j.jss.2010.07.024] [Reference Citation Analysis]
37 Bonne L, Verslype C, Laenen A, Cornelissen S, Deroose CM, Prenen H, Vandecaveye V, Van Cutsem E, Maleux G. Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results. Radiol Oncol 2017;51:74-80. [PMID: 28265235 DOI: 10.1515/raon-2017-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
38 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715-731. [PMID: 28609357 DOI: 10.1097/mpa.0000000000000846] [Cited by in Crossref: 127] [Cited by in F6Publishing: 57] [Article Influence: 31.8] [Reference Citation Analysis]
39 Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol 2013;30:28-38. [PMID: 24436515 DOI: 10.1055/s-0033-1333651] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
40 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
41 Yu X, Gu J, Wu H, Fu D, Li J, Jin C. Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Oncol. 2018;2018:6273947. [PMID: 30538745 DOI: 10.1155/2018/6273947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Nadler A, Cukier M, Milot L, Singh S, Law CH. Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach. Can J Surg 2014;57:E2-8. [PMID: 24666455 DOI: 10.1503/cjs.014112] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Grimme FAB, Seesing MFJ, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C, de Wilt JHW; On behalf of the Dutch Liver Surgery Working Group. Liver Resection for Hepatic Metastases from Soft Tissue Sarcoma: A Nationwide Study. Dig Surg. 2019;36:479-486. [PMID: 30253419 DOI: 10.1159/000493389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
44 Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040. [PMID: 23509630 DOI: 10.1155/2013/235040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
45 Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009;:CD007118. [PMID: 19160322 DOI: 10.1002/14651858.CD007118.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
46 Kawaguchi Y, De Bellis M, Panettieri E, Duwe G, Vauthey JN. Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Surg Oncol Clin N Am 2021;30:205-18. [PMID: 33220806 DOI: 10.1016/j.soc.2020.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Huang J, Li Q, Zheng Y, Shen J, Li B, Zou R, Wang J, Yuan Y. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 2014;14:818. [PMID: 25376591 DOI: 10.1186/1471-2407-14-818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
48 Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193. [PMID: 22518323 DOI: 10.1155/2012/819193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
49 Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773. [PMID: 15492556 DOI: 10.1097/01.sla.0000143252.02142.3e] [Cited by in Crossref: 166] [Cited by in F6Publishing: 140] [Article Influence: 9.2] [Reference Citation Analysis]
50 Hashimoto K, Yasumoto T, Fujie Y, Fujita J, Ohnishi T. Liver metastasis from pancreatic neuroendocrine tumors after pancreaticoduodenectomy successfully treated by radiofrequency ablation combined with transcatheter arterial embolization: A case report. Int J Surg Case Rep 2020;77:147-51. [PMID: 33161287 DOI: 10.1016/j.ijscr.2020.10.130] [Reference Citation Analysis]
51 Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27:358-367. [PMID: 26361405 DOI: 10.3978/j.issn.1000-9604.2015.05.02] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
52 Iwazawa J, Ohue S, Yasumasa K, Mitani T. Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver. World J Radiol 2010; 2(12): 468-471 [PMID: 21225002 DOI: 10.4329/wjr.v2.i12.468] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
53 Cheung TT, Chok KS, Chan AC, Tsang S, Dai JW, Lang BH, Yau T, Chan SC, Poon RT, Fan ST, Lo CM. Long term survival analysis of hepatectomy for neuroendocrine tumour liver metastases. ScientificWorldJournal 2014;2014:524045. [PMID: 24526905 DOI: 10.1155/2014/524045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
54 Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? Curr Oncol Rep. 2012;14:249-256. [PMID: 22434313 DOI: 10.1007/s11912-012-0232-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
55 Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951-1960. [PMID: 18709512 DOI: 10.1007/s11605-008-0640-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 5.4] [Reference Citation Analysis]
56 Pasqual EM, Bertozzi S, Londero AP, Bacchetti S, Lorenzin D, Pasqualucci A, Moccheggiani F, Federici A, Vivaverlli M, Risaliti A. Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors. Oncol Lett 2016;12:3563-70. [PMID: 27900037 DOI: 10.3892/ol.2016.5045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
58 Del Prete M, Fiore F, Modica R, Marotta V, Marciello F, Ramundo V, Di Sarno A, Carratù A, di Roseto Cde L, Tafuto S, Tatangelo F, Baldelli R, Colao A, Faggiano A; Multidisciplinary Group for NeuroEndocrine Tumors of Naples. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res 2014;33:43. [PMID: 24887262 DOI: 10.1186/1756-9966-33-43] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
59 Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 2015;5:e008248. [PMID: 25991462 DOI: 10.1136/bmjopen-2015-008248] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
60 Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Campagnaro T, Ercolani G, Conci S, Giuliante F, Dore A, Ferrero A, Torzilli G, Grazi GL, Ratti F, Cucchetti A, De Rose AM, Russolillo N, Cimino M, Perri P, Guglielmi A, Iacono C. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. J Gastrointest Surg 2019;23:93-100. [PMID: 30242647 DOI: 10.1007/s11605-018-3973-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Tai E, Kennedy S, Farrell A, Jaberi A, Kachura J, Beecroft R. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. Curr Oncol 2020;27:e537-46. [PMID: 33380868 DOI: 10.3747/co.27.6205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Atema JJ, Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ. Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions. HPB (Oxford). 2015;17:38-45. [PMID: 25041879 DOI: 10.1111/hpb.12319] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
63 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
64 Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH. Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018;18:84. [PMID: 29902988 DOI: 10.1186/s12876-018-0817-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
65 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
66 Mulkeen AL, Yoo PS, Cha C. Less common neoplasms of the pancreas. World J Gastroenterol 2006; 12(20): 3180-3185 [PMID: 16718837 DOI: 10.3748/wjg.v12.i20.3180] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
67 Neperud J, Mahvash A, Garg N, Murthy R, Szklaruk J. Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy? World J Radiol 2013; 5(6): 241-247 [PMID: 23807902 DOI: 10.4329/wjr.v5.i6.241] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
68 Fernández-cruz L, Romero J, Zelaya R, Olvera C, Maglio L. Surgical strategies for nonfunctioning neuroendocrine pancreatic tumors and for other pancreatic neoplasms associated with multiple endocrine neoplasia type 1. The American Journal of Surgery 2007;194:S143-7. [DOI: 10.1016/j.amjsurg.2007.05.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol. 2012;2012:471203. [PMID: 22319651 DOI: 10.1155/2012/471203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
70 Feuerecker B, Scheidhauer K, Schwaiger M, Mustafa M. Intra-arterial radiopeptide therapy of hepatic metastases of neuroendocrine tumors: a systematic review. Clin Transl Imaging 2017;5:89-99. [DOI: 10.1007/s40336-016-0220-9] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
71 Haugvik SP, Labori KJ, Edwin B, Mathisen Ø, Gladhaug IP. Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal. 2012;2012:357475. [PMID: 23304085 DOI: 10.1100/2012/357475] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
72 Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann Saudi Med. 2014;34:279-290. [PMID: 25811199 DOI: 10.5144/0256-4947.2014.279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
73 Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M. Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg. 2012;16:1981-1992. [PMID: 22829240 DOI: 10.1007/s11605-012-1951-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
74 Bacchetti S, Pasqual EM, Bertozzi S, Londero AP, Risaliti A. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3:243-251. [PMID: 25493256 DOI: 10.3978/j.issn.2227-684x.2014.02.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
75 Fendrich V, Michl P, Habbe N, Bartsch DK. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2(10): 367-373 [PMID: 21160945 DOI: 10.4254/wjh.v2.i10.367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
76 Yamamoto H, Hemmi H, Gu JY, Sekimoto M, Doki Y, Mori M. Minute liver metastases from a rectal carcinoid: A case report and review. World J Gastrointest Surg 2010; 2(3): 89-94 [PMID: 21160856 DOI: 10.4240/wjgs.v2.i3.89] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Zlate AC, Alexandrescu ST, Grigorie RT, Gramaticu IM, Kraft A, Dumitru R, Tomescu D, Popescu I. THE ROLE OF SURGERY IN A PATIENT WITH CARCINOID SYNDROME, COMPLICATED BY CARCINOID HEART DISEASE. Acta Endocrinol (Buchar) 2018;14:117-21. [PMID: 31149245 DOI: 10.4183/aeb.2018.117] [Reference Citation Analysis]
78 Jeon YB, Yun S, Choi D. Transfusion free radical antegrade modular pancreaticosplenectomy of metastatic neuroendocrine tumor of the pancreas in Jehovah's Witness patient. Ann Surg Treat Res 2015;88:106-10. [PMID: 25692122 DOI: 10.4174/astr.2015.88.2.106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
79 Harring TR, Nguyen NT, Goss JA, O’Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol. 2011;2011:154541. [PMID: 22013537 DOI: 10.4061/2011/154541] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
80 Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011;2011:452343. [PMID: 22121491 DOI: 10.4061/2011/452343] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
81 Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166-175. [PMID: 30343949 DOI: 10.1016/j.surg.2018.04.070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
82 Peng Y, Tan S, Zhu G, Fang C, He P, Peng F, Gan Y, Tian J, Su S, Yang X, Li B. Successful application of ICG fluorescence imaging technology in rectal neuroendocrine tumor liver metastasis. Photodiagnosis Photodyn Ther 2021;37:102653. [PMID: 34848376 DOI: 10.1016/j.pdpdt.2021.102653] [Reference Citation Analysis]
83 Landen S, Elens M, Vrancken C, Nuytens F, Meert T, Delugeau V. Giant hepatic carcinoid: a rare tumor with a favorable prognosis. Case Rep Surg. 2014;2014:456509. [PMID: 24653852 DOI: 10.1155/2014/456509] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
84 McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258-275. [PMID: 25493258 DOI: 10.3978/j.issn.2227-684x.2014.06.03] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
85 Paniccia A, Edil BH, Schulick RD. Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg 2015;77:395-402. [PMID: 26722203 DOI: 10.1007/s12262-015-1360-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
86 Musholt TJ, Lang H. [Indications and operative procedures for neuroendocrine liver metastases]. Chirurg 2009;80:113-21. [PMID: 19212693 DOI: 10.1007/s00104-008-1614-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
87 Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012;105:595-600. [PMID: 22006521 DOI: 10.1002/jso.22118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
88 Palesty JA, Al-Kasspooles M, Gibbs JF. Patient selection for surgical management of primary and metastatic liver cancers: current perspectives. Semin Intervent Radiol 2006;23:13-20. [PMID: 21326716 DOI: 10.1055/s-2006-939837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Blonski WC, Reddy KR, Shaked A, Siegelman E, Metz DC. Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature. World J Gastroenterol. 2005;11:7676-7683. [PMID: 16437698 DOI: 10.3748/wjg.v11.i48.7676] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
90 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg. 2011;396:1145-1156. [PMID: 21523447 DOI: 10.1007/s00423-011-0794-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
92 Goode JA, Matson MB. Embolisation of cancer: what is the evidence? Cancer Imaging 2004;4:133-41. [PMID: 18250022 DOI: 10.1102/1470-7330.2004.0021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
93 Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Åkerström G, Hellman P. Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors. World J Surg 2008;32:930-8. [DOI: 10.1007/s00268-008-9510-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
94 Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013;216:123-34. [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
95 Vogel A, Gupta S, Zeile M, von Haken R, Brüning R, Lotz G, Vahrmeijer A, Vogl T, Wacker F. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review. Adv Ther 2017;33:2122-38. [PMID: 27798773 DOI: 10.1007/s12325-016-0424-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
96 Grozinsky-Glasberg S, Kaltsas G, Kaltsatou M, Lev-Cohain N, Klimov A, Vergadis V, Uri I, Bloom AI, Gross DJ. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice. Endocrine. 2018;60:499-509. [PMID: 29383678 DOI: 10.1007/s12020-018-1537-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
97 Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health 2013;16:46-56. [PMID: 23337215 DOI: 10.1016/j.jval.2012.09.005] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, Xu Y, Chi T, Zhao H, Wang W, Cui Q, Zhong S, Huang J, Mao Y. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. Medicine (Baltimore) 2015;94:e388. [PMID: 25590842 DOI: 10.1097/MD.0000000000000388] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
99 Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D'Angelica M, Harrison LE, DeMatteo RP. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg. 2005;241:269-276. [PMID: 15650637 DOI: 10.1097/01.sla.0000150244.72285.ad] [Cited by in Crossref: 142] [Cited by in F6Publishing: 118] [Article Influence: 8.4] [Reference Citation Analysis]
100 Zhang X, Song J, Liu P, Mazid MA, Lu L, Shang Y, Wei Y, Gong P, Ma L. A modified M-stage classification based on the metastatic patterns of pancreatic neuroendocrine neoplasms: a population-based study. BMC Endocr Disord 2018;18:73. [PMID: 30340569 DOI: 10.1186/s12902-018-0301-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol 2015;22:e305-15. [PMID: 26300681 DOI: 10.3747/co.22.2603] [Reference Citation Analysis]
102 Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database. J Gastrointest Oncol 2019;10:869-77. [PMID: 31602324 DOI: 10.21037/jgo.2019.05.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
103 Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12:427-433. [PMID: 20662794 DOI: 10.1111/j.1477-2574.2010.00198.x] [Cited by in Crossref: 136] [Cited by in F6Publishing: 110] [Article Influence: 12.4] [Reference Citation Analysis]
104 Williamson JM, Thorn CC, Spalding D, Williamson RC. Pancreatic and peripancreatic somatostatinomas. Ann R Coll Surg Engl 2011;93:356-60. [PMID: 21943457 DOI: 10.1308/003588411X582681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Ferrel B, Franko J, Tee MC. Rare case of pancreatic neuroendocrine tumour presenting as paraneoplastic hypercalcaemia. BMJ Case Rep 2021;14:e240786. [PMID: 33858893 DOI: 10.1136/bcr-2020-240786] [Reference Citation Analysis]
106 Stump R, Haueis S, Kalt N, Tschuor C, Limani P, Raptis DA, Puhan MA, Breitenstein S. Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews. JMIR Res Protoc. 2013;2:e58. [PMID: 24366112 DOI: 10.2196/resprot.2891] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
107 Vyleta M, Coldwell D. Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011;2011:785315. [PMID: 22235376 DOI: 10.4061/2011/785315] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
108 Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007;11:1460-1467; discussion 1467-1469. [PMID: 17846854 DOI: 10.1007/s11605-007-0263-3] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 7.4] [Reference Citation Analysis]
109 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
111 Kjaer J, Stålberg P, Crona J, Welin S, Hellman P, Thornell A, Norlen O. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open 2021;5:zrab062. [PMID: 34291287 DOI: 10.1093/bjsopen/zrab062] [Reference Citation Analysis]
112 Weikert T, Maas OC, Haas T, Klarhöfer M, Bremerich J, Forrer F, Sauter AW, Sommer G. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. Contrast Media Mol Imaging 2019;2019:1517208. [PMID: 31787860 DOI: 10.1155/2019/1517208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Quartey B. Primary Hepatic Neuroendocrine Tumor: What Do We Know Now? World J Oncol. 2011;2:209-216. [PMID: 29147250 DOI: 10.4021/wjon341w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
114 Taner T, Atwell TD, Zhang L, Oberg TN, Harmsen WS, Slettedahl SW, Kendrick ML, Nagorney DM, Que FG. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford). 2013;15:190-195. [PMID: 23374359 DOI: 10.1111/j.1477-2574.2012.00528.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
115 Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials 2018;19:390. [PMID: 30016989 DOI: 10.1186/s13063-018-2782-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
116 Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford). 2010;12:361-379. [PMID: 20662787 DOI: 10.1111/j.1477-2574.2010.00175.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
117 Cossetti RJ, Bezerra RO, Gumz B, Telles A, Costa FP. Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases. World J Surg Oncol. 2012;10:82. [PMID: 22591909 DOI: 10.1186/1477-7819-10-82] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
118 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
119 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
120 Veenendaal LM, Borel Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006;4:35. [PMID: 16800893 DOI: 10.1186/1477-7819-4-35] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
121 Zhou B, Zhan C, Ding Y, Yan S, Zheng S. Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. Onco Targets Ther 2018;11:975-82. [PMID: 29503572 DOI: 10.2147/OTT.S158171] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
122 Schell SR, Camp ER, Caridi JG, Hawkins IF Jr. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 2002;6:664-70. [PMID: 12399054 DOI: 10.1016/s1091-255x(02)00044-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
123 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013;1:6. [PMID: 25332951 DOI: 10.3978/j.issn.2305-5839.2013.01.08] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
124 Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941-960. [PMID: 22886480 DOI: 10.1007/s00535-012-0642-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
125 Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27:4995-5005. [PMID: 28677067 DOI: 10.1007/s00330-017-4856-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
126 Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
127 Davi MV, Pia A, Guarnotta V, Pizza G, Colao A, Faggiano A; NIKE Group. The treatment of hyperinsulinemic hypoglycaemia in adults: an update. J Endocrinol Invest 2017;40:9-20. [PMID: 27624297 DOI: 10.1007/s40618-016-0536-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
128 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB;  UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 353] [Cited by in F6Publishing: 280] [Article Influence: 32.1] [Reference Citation Analysis]
129 Čolović RB, Matić SV, Micev MT, Grubor NM, Atkinson HD, Latinčić SM. Two synchronous somatostatinomas of the duodenum and pancreatic head in one patient. World J Gastroenterol 2009; 15(46): 5859-5863 [PMID: 19998510 DOI: 10.3748/wjg.15.5859] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
130 Kaçmaz E, Heidsma CM, Besselink MGH, Dreijerink KMA, Klümpen HJ, Nieveen van Dijkum EJM, Engelsman AF. Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E403. [PMID: 30909512 DOI: 10.3390/jcm8030403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
131 Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L. The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatol 2013;2013:702167. [PMID: 27335831 DOI: 10.1155/2013/702167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:iv1-i16. [PMID: 15888809 DOI: 10.1136/gut.2004.053314] [Cited by in Crossref: 173] [Cited by in F6Publishing: 192] [Article Influence: 10.2] [Reference Citation Analysis]
133 Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557-577. [PMID: 23591432 DOI: 10.1097/mpa.0b013e31828e34a4] [Cited by in Crossref: 326] [Cited by in F6Publishing: 141] [Article Influence: 36.2] [Reference Citation Analysis]
134 Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392-2397. [PMID: 17960455 DOI: 10.1007/s00268-007-9264-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
135 Scoville SD, Xourafas D, Ejaz AM, Tsung A, Pawlik T, Cloyd JM. Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World J Gastrointest Surg 2020; 12(4): 159-170 [PMID: 32426095 DOI: 10.4240/wjgs.v12.i4.159] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
136 Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience. Cancer Control. 2017;24:1073274817729076. [PMID: 28975822 DOI: 10.1177/1073274817729076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
137 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
138 Haider M, Jiang BG, Parker JA, Bullock AJ, Goehler A, Tsai LL. Use of MRI and Ga-68 DOTATATE for the detection of neuroendocrine liver metastases. Abdom Radiol (NY) 2021. [PMID: 34757459 DOI: 10.1007/s00261-021-03341-z] [Reference Citation Analysis]
139 Wilson HM. Chronic subacute bowel obstruction caused by carcinoid tumour misdiagnosed as irritable bowel syndrome: a case report. Cases J 2009;2:78. [PMID: 19161610 DOI: 10.1186/1757-1626-2-78] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
140 Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am 2015;53:933-71. [PMID: 26321447 DOI: 10.1016/j.rcl.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
141 DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7; discussion 547-8. [PMID: 11573047 DOI: 10.1097/00000658-200110000-00013] [Cited by in Crossref: 179] [Cited by in F6Publishing: 133] [Article Influence: 8.5] [Reference Citation Analysis]
142 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
143 Khan H, Pillarisetty VG, Katz SC. The prognostic value of liver tumor T cell infiltrates. J Surg Res 2014;191:189-95. [PMID: 25033707 DOI: 10.1016/j.jss.2014.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
144 Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol 2012;7:107-16. [PMID: 22707276 DOI: 10.1007/s11523-012-0219-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
145 Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009;6:143-152. [PMID: 19190591 DOI: 10.1038/ncponc1326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
146 Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 2009;6:419-28. [DOI: 10.1038/nrclinonc.2009.82] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
147 Perälä J, Klemola R, Kallio R, Li C, Vihriälä I, Salmela PI, Tervonen O, Sequeiros RB. MRI-guided laser ablation of neuroendocrine tumor hepatic metastases. Acta Radiol Short Rep 2014;3:2047981613499753. [PMID: 24778794 DOI: 10.1177/2047981613499753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
148 Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience. J Gastrointest Oncol 2019;10:118-27. [PMID: 30788167 DOI: 10.21037/jgo.2018.10.05] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
149 Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845-851; discussion 852-853. [PMID: 17122609 DOI: 10.1097/01.sla.0000246951.21252.60] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 7.6] [Reference Citation Analysis]
150 Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011;28 Suppl 1:S286-90. [PMID: 21107755 DOI: 10.1007/s12032-010-9750-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]